About — InterCure

Our Mission

"To set the global standard for pharmaceutical cannabis — through rigorous science, clinical-grade retail, and the world's most powerful brand portfolio."

InterCure Ltd. — Company Mission Statement

2013

Founded

12

Profitable Half-Years

2

Stock Exchanges

350+

Employees

What We Stand For

Our Core Values

Everything we build — every pharmacy, every clinical trial, every brand partnership — reflects these six principles.

01

🔬

Science First

Every product, every dosage, every strain recommendation is backed by clinical evidence. Our partnership with the Technion ensures our decisions are driven by data, not marketing.

02

🏥

Patient Dignity

Patients deserve the same level of care and professionalism they receive in any pharmacy. Givol exists to provide that — a clinical-grade experience that respects patients as people, not consumers.

03

🌍

Global Ambition

We don't think locally. Every system we build, every brand we sign, every technology we deploy is designed to scale internationally — from Israel to Germany and beyond.

04

📈

Financial Discipline

12 consecutive profitable half-years is not an accident. We grow deliberately — prioritizing sustainable margins over headline metrics, and operational efficiency over rapid burn.

05

🤝

Partnership Integrity

Our relationships with Cookies, The Flowery, Cannasoul, and the Technion are built on mutual respect and shared vision. We are long-term partners, not transactional operators.

06

⚙️

Operational Excellence

Botanico AI is the embodiment of this value — technology that eliminates inefficiency at every layer of the supply chain, from cultivation planning to pharmacy shelves.

Leadership

Executive Team

The leadership driving InterCure's position as the leading pharmaceutical cannabis company outside North America.

Alexander Rabinovich

Founder & Chief Executive Officer

Alexander is the founder and CEO of InterCure. He has led the company from its earliest days to its position as the leading pharmaceutical cannabis company outside North America, dual-listed on NASDAQ (INCR) and the Tel Aviv Stock Exchange. Under his leadership, InterCure has built a vertically integrated seed-to-sale platform serving over 100,000 patients across five international territories.

Einat Zehavi

Chief Executive Officer, Retail

Einat leads InterCure's retail division as CEO of Kan Olam, the group's retail holding company. She oversees the Givol and Leon Pharm pharmacy networks, together one of Israel's largest licensed medical cannabis retail footprints, with responsibility for commercial strategy, patient experience, brand execution, and operational standards across the chain.

Amos Cohen

Chief Financial Officer

Amos serves as Chief Financial Officer of InterCure, overseeing the company's financial operations, planning, and reporting across its dual NASDAQ and Tel Aviv Stock Exchange listing. He leads capital markets activity, investor relations, financial controls, and the funding architecture supporting the group's continued growth across international territories.

Omer Layani

Chief Technology Officer

Omer leads InterCure's technology function across cultivation facilities, raw-material quality systems, and the group's portfolio of premium American brands, including The Flowery, Preferred Gardens, Doja, Wizard Tree, and Runtz. He owns the company's automation and AI roadmap, building the infrastructure to take InterCure into its next phase as a technology-led pharmaceutical cannabis company.

Dor Hershkowitz

VP, Global Business Development

Dor leads InterCure's global business development, currently focused on the company's expansion into Europe. He builds the commercial partnerships, distribution channels, and market-entry frameworks that translate InterCure's pharmaceutical-grade platform into international growth, with primary responsibility for establishing the company's presence across key European markets.

Yarin Lidor

Head of Marketing

Yarin leads InterCure's marketing function, with responsibility for marketing strategy and brand across the company's portfolio. Drawing on a strong technical background alongside deep marketing expertise, he builds the automation and AI infrastructure that scales brand presence and integrates data-driven execution into the creative work behind InterCure's pharmaceutical and premium consumer brands.

Dean Simhon

Head of Supply Chain

Dean is a 13-year cannabis industry veteran and pioneer of Israeli medical cannabis, with expertise in patient support, pharmacy operations, and specialized network development. He leads InterCure's global supply chain, from genetics and cultivation partnerships in Canada and Israel through EU-GMP-certified manufacturing, import and export, and delivery to patients, with full responsibility for continuity, quality, and pharmaceutical-grade compliance.

Science

Advisory Scientific Board

Prof. Dedi Meiri

Chairperson, Scientific Advisory Board

Prof. Meiri chairs InterCure's Scientific Advisory Board and is the founder of Cannasoul, the company's research and analytics partner. An Associate Professor at the Technion (Israel Institute of Technology), he heads the Laboratory of Cancer Biology and Cannabinoid Research, has authored over 80 peer-reviewed papers, and leads work mapping the Entourage Effect across 120+ cannabinoids.

Company History

Our Journey

From a single pharmacy concept in Tel Aviv to a dual-listed global pharmaceutical cannabis leader — a decade of deliberate, profitable growth.

Today

Global Market Leader

$85M revenue · 25 pharmacies · 6 global brands · 12 profitable half-years · Operations in IL & DE

2013

Company Founded

Alexander Rabinovich establishes InterCure in Tel Aviv with a vision to build the world's most trusted pharmaceutical cannabis company.

2016

First Givol Pharmacy Opens

The inaugural Givol pharmacy opens in Tel Aviv, setting a new standard for clinical-grade cannabis retail in Israel.

2018

TASE Listing

InterCure lists on the Tel Aviv Stock Exchange, raising capital to accelerate pharmacy network expansion across Israel.

2020

Cookies Partnership Signed

InterCure secures the exclusive international distribution rights for Cookies — the world's most recognised cannabis brand — outside North America.

2021

NASDAQ Dual Listing

InterCure becomes one of the first Israeli cannabis companies to list on NASDAQ, bringing international institutional capital to the business.

2022

Botanico AI Launched

Proprietary AI platform deployed across the full Givol network, achieving 98% forecast precision for supply chain planning.

2023

Cannasoul × Technion Partnership

Exclusive R&D partnership signed with Cannasoul Analytics and Prof. Dedi Meiri of the Technion. 11 active clinical trials initiated.

2024

Germany Expansion — Cookies Corners

Following Germany's historic cannabis legalization, Givol opens Cookies Corners in Frankfurt and Berlin — the largest medical cannabis retail footprint in Europe. FY2024 revenue reaches $85M.

Sustainability

ESG Commitments

We believe that a sustainable business is a profitable business. Our ESG framework is embedded in operations — not a marketing afterthought.

E

Environmental

Our cultivation operations target net-zero water usage through closed-loop hydroponics. All Givol pharmacy locations use LED lighting with 40% lower energy consumption than industry standard. We are targeting carbon neutrality across Israeli operations by 2027.

S

Social

InterCure employs 350+ people across Israel and Germany, with an above-market employee benefits package. We run the Givol Patient Access Program, which provides subsidised cannabis access to low-income patients with chronic conditions who qualify under Israeli medical cannabis regulations.

G

Governance

Our board comprises a majority of independent directors, including two external directors as required under Israeli securities law. All related-party transactions require independent approval. Dual-listed on NASDAQ and TASE, InterCure meets the highest standards of financial disclosure across two jurisdictions.

Where We Operate

Global Presence

Two markets. One vision. A presence built for expansion.

🇮🇱

Israel

Headquarters & Core Market

Corporate HQ in Herzliya. 20+ Givol pharmacies spanning Tel Aviv, Jerusalem, Haifa, Be'er Sheva and regional centres. Home to the Cannasoul R&D lab (Technion, Haifa) and Botanico AI engineering team. Israel is the world's most mature medical cannabis market per capita — and InterCure's operational proving ground.

🇩🇪

Germany

EU Distribution Hub & Growth Market

EU distribution headquarters in Frankfurt. Cookies Corners operating in Frankfurt and Berlin — the only dedicated premium medical cannabis retail experience in Germany. Following Germany's 2024 legalization, InterCure is positioned as the first-mover with EU-GMP certified inventory, pharmacy relationships, and an established brand presence that no new entrant can replicate quickly.

Get in Touch

Contact InterCure

Whether you're a patient, investor, brand partner, or journalist — we'd like to hear from you.

📧

General Enquiries

office@canndoc-pharma.com

📈

Investor Relations

View IR Dashboard →

📍

Headquarters

85 Medinat Hayehudim St.
Herzliya, 4676672, Israel

Quick Links

Our Ecosystem → Investor Relations → SEC Filings → Brand Portfolio → Press Releases →